Certara also contributes to a student scholarship fund to ensure that aspiring pharmacometrics researchers can attend the conference
PRINCETON, NJ – 2015 年 5 月 28 日 – Certara®, the global biosimulation technology-enabled drug development consultancy, today announced that it will be presenting two workshops and 10 posters at the 2015 Population Approach Group in Europe (PAGE) Annual Meeting. PAGE is a UK-based, nonprofit organization, which is committed to taking a population approach to data analysis. This year’s conference will be held from June 2-5 in Hersonissos, Crete, Greece.
“Certara aspires to play an active role in educating new pharmacometrics leaders around the world,” said the company’s Chief Executive Officer Edmundo Muniz, M.D., Ph.D. “As a result, we co-sponsor the annual PAGE Scholarship, which enables a select group of students with no other financial support to attend this prestigious meeting. Eight scholarships were awarded this year to students in Brazil, the Netherlands, Greece, China, and Thailand.”
Certara’s contribution to this year’s meeting includes the following presentations:
Monday, June 1 and Tuesday, June 2
Phoenix Non Linear Mixed Effect (NLME) Modeling: Introductory and Advanced Workshop
This two-day workshop will introduce participants to the Phoenix® platform and the model-building approach for continuous and categorical responses. Emphasis will be on six test cases and the Phoenix graphical interface that has been especially developed to facilitate the generation of complex mathematical models.
Tuesday, June 2
Parameter Estimation and Pharmacodynamics (PE/PD) Workshop
This hands-on session will focus on the pharmacometrics features within the Simcyp® platform. Population-based physiologically-based pharmacokinetic (PBPK) models can be connected to PD models, enabling concentrations at sites of action to drive pharmacological and toxicological effects and provide valuable insights into covariate recognition and dissect PK and PD inter-individual variability. This course will provide a bridge between mechanistic covariate recognition, complex model fitting and rational design of studies.
Wednesday, June 3; 10:45 a.m. – 12:15 p.m.
I-25: “Building of a Virtual Pediatric Cancer Population for Physiologically-based Pharmacokinetic Modeling and Simulation in Neonates, Infants, and Children.”Bonner, J., Walsh, C., Johnson, T., Neuhoff, S., Greystoke, A., Veal, G.
I-36: “Application of Simcyp’s R Library Package in Simulation and Prediction of Metoprolol Compliance Using a Single Plasma Concentration Sample.”Cain, T., Barnett, A., Jamei, M.
I-43: “Model-based Simulation Assessment of Personalized Healthcare Strategies. A Case for Siponimod in Multiple Sclerosis.”Chanu, P., Mercier, F.
I-51: “Emerging Covariates on the Pharmacokinetics of Monoclonal Antibodies: Do Current PBPK Models Account for the Covariates Identified in POPPK Studies?”Chetty, M., Gill, K., Machavaram, K., Li, L., Gardner, I., Rostami, A., Jamei, M.
I-57: “A Comparison of Two Stage and Joint Tumor Growth Inhibition-progression Free Survival Modeling Approach to Simulate Clinical Outcome in Oncology.”Claret, L., Bruno, R., Wang, B., Marchand, M., Li, C., Girish, S., Jin, J., Quartino, A.
Wednesday, June 3; 3:15-4:40 p.m.
II-52: “Use of a Physiologically-based Pharmacokinetic Modeling and Simulation Approach to Rationalize Actinomycin D Dosing in Pediatric Oncology.”Walsh, C., Bonner, J., Boddy, A., Johnson, T., Neuhoff, S., Veal, G.
II-58: “Towards More Realistic Clinical Trial Simulation: Establishing Inter-correlations between Several Cytochrome P450 Enzyme Abundances in Human Liver.”Wedagedera, J., Abduljalil, K., Cain, T., Achour, B., Pathak, S., Dunlavey, M., Jamei, M., Rostami, A.
Thursday, June 4; 10:20-11:45 a.m.
III-35: “Tumor Growth Inhibition Modeling of Onartuzumab in Combination with Erlotinib Does Not Suggest Dose Intensification Would Improve Outcome in Patients with 2nd and 3rd Line Non-small Cell Lung Cancer.”Han, K., Chanu, P., Jonsson, F., Winter, H., Bruno, R., Jin, J., Stroh, M.
Thursday, June 4; 3:20-4:40 p.m.
IV-08: “Challenges in Predicting the Drug-drug Interaction between Dextromethorphan and Rifampicin Using a PBPK Model that Includes Three Metabolites of Dextromethorphan.”Gaohua L., Crewe K., Rose, R., Rostami, A., Rowland Yeo, K., Jamei M.
IV-31: “Extended Validation of a Peripheral Sampling Site in PBPK Modeling using Clarithromycin, Dextromethorphan, Dextrorphan, Erythromycin, Lidocaine and Tramadol.”Musther H., Gill K., Lu, G., Pathak, S., Jamei, M.
For more information about the PAGE Annual Meeting, please visit http://www.page-meeting.org/default.asp?id=39&keuze=meeting.
Certara is a global biosimulation technology-enabled drug development consultancy. Its customers include hundreds of biopharmaceutical companies around the globe, together with several regulatory agencies. Certara’s solutions, which span the discovery, preclinical and clinical stages of drug development, enable data-driven decisions, leading to more precisely designed trials with a reduced risk of failure and improved subject safety. For more information, visit http://www.certara.com.
Ellen Leinfuss, 609-216-9586
Chief Marketing Officer
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions